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Abstract
Background: Regional citrate or heparin is often prescribed as an anticoagulant for continuous renal replacement
therapy (CRRT). However, their efficacy and safety remain controversial. Therefore, we performed this meta-analysis
to compare these two agents and to determine whether the currently available evidence is sufficient and
conclusive by using trial sequential analysis (TSA).
Methods: We searched for relevant studies in PubMed, Embase, the Cochrane Library databases and the China
National Knowledge Infrastructure (CNKI) Database from database inception until September 2015. We selected
randomized controlled trials comparing regional citrate with heparin in adult patients with acute kidney injury (AKI)
who were prescribed CRRT.
Results: Fourteen trials (n = 1134) met the inclusion criteria. Pooled analyses showed that there was no difference
in mortality between the regional citrate and heparin groups (relative risk (RR) 0.97, 95 % confidence interval (CI)
0.84, 1.13, P > 0.05), which was confirmed by TSA. Compared with heparin, regional citrate significantly prolonged
the circuit life span in the continuous venovenous haemofiltration (CVVH) subgroup (mean difference (MD) 8.18,
95 % CI 3.86, 12.51, P < 0.01) and pre-dilution subgroup (MD 17.51, 95 % CI 9.85, 25.17, P < 0.01) but not in the
continuous venovenous haemodiafiltration (CVVHDF) subgroup (MD 28.60, 95 % CI −3.52, 60.73, P > 0.05) or
post-dilution subgroup (MD 13.06, 95 % CI −2.36, 28.48, P > 0.05). However, the results were not confirmed by
TSA. A reduced risk of bleeding was found in the regional citrate compared with the systemic heparin group
(RR 0.31, 95 % CI 0.19, 0.51, P < 0.01) and TSA provided conclusive evidence. Fewer episodes of heparin-induced
thrombocytopoenia (HIT) (RR 0.41, 95 % CI 0.19, 0.87, P = 0.02) and a greater number of episodes of hypocalcaemia
(RR 3.96, 95 % CI 1.50, 10.43, P < 0.01) were found in the regional citrate group. However, TSA did not provide
conclusive evidence.
Conclusion: In adult patients with AKI, there is no difference in mortality between the regional citrate and heparin
treated groups. However, regional citrate is more efficacious in prolonging circuit life span and reducing the risk of
bleeding and should be recommended as the priority anticoagulant for critically ill patients who require CRRT.
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Background
Continuous renal replacement therapy (CRRT) has been
widely used in critically ill patients with acute kidney in-
jury (AKI) and anticoagulation of the extracorporeal
blood is necessary to maintain the patency of the circuit
[1]. In recent decades, different anticoagulation strategies
have been used in clinical settings [2] and heparin is the
most commonly used anticoagulant. Although heparin
has the advantages of low cost, easy monitoring and
simple reversal, it may increase bleeding. Additionally,
there is the risk of heparin-induced thrombocytopenia
type II (HIT-II) that can result in life-threatening
complications [3]. Regional citrate anticoagulation
(RCA), which was first introduced into clinical use in
the early 1980s [4], has been recommended as the
most suitable form of CRRT regional circuit anticoa-
gulation [5] and has been safely used even in patients
with severe liver dysfunction [6]. However, citrate in-
fusion in critically ill patients impacts a variety of
metabolic systems, which can lead to hypocalcaemia,
metabolic alkalosis and citrate toxicity. These poten-
tial disturbances can be resolved by careful monitor-
ing, adherence to treatment protocols, and oversight
by trained staff in clinical practice [7]. Previous meta-
analyses [8–10] have evaluated the efficacy and safety
of regional citrate versus heparin anticoagulation.
However, the results have yielded large discrepancies.
Furthermore, a single-centre [11] and two multi-centre
[12, 13] randomized controlled trials (RCTs) that were
published recently were not included in these meta-
analyses. To provide the most recent available evidence,
we performed this meta-analysis comparing the two
agents. We further applied trial sequential analysis (TSA)
to determine whether the currently available evidence was
sufficient and conclusive.
Methods
The Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA statement) guidelines were
used to perform this meta-analysis [14].
Search strategy and information sources
A search of the PubMed (US National Library of
Medicine, Bethesda, MD, USA), Cochrane Library
databases, EMBASE and China National Knowledge
Infrastructure (www.cnki.net) databases from database
inception to September 2015 was performed. Specific
search strategies were developed for each database, using
different combinations and variations of the search
terms “anticoagulation,” “citrate,” “heparin,” “continuous
renal replacement therapy (CRRT),” “continuous venove-
nous haemofiltration (CVVH),” “continuous venovenous
hemodialysis (CVVHD),” “continuous venovenous hemo-
diafiltration (CVVHDF),” and “Randomized Controlled
Trial.” The search was limited to human subjects, and no
language restrictions were applied. Further searches were
performed if necessary by manually reviewing conference
proceedings and the references of review articles.
Inclusion and exclusion criteria
The inclusion criteria were as follows: (1) study design:
RCTs; (2) comparison: evaluating the efficacy and
safety of regional citrate compared with heparin antic-
oagulation for CRRT; and (3) population: conducted
in critically ill adult patients (>16 years old). Exclu-
sion criteria were as follows: (1) studies including pa-
tients with liver failure or hemorrhagic disorders; and
(2) data from the published results could not be ex-
tracted and analyzed.
Study selection and data extraction
Two investigators (CL and ZM) independently per-
formed the study selection. Disagreements between the
two investigators were resolved by third party adjudica-
tion (FZ). A standard form was used to collect data from
each study. The form included first author, year of publi-
cation, study design, number of patients, number of
circuits, patient characteristics, circuit life span and
details of complications. The primary outcomes were
mortality and circuit life span. Secondary outcomes
included bleeding events, HIT, metabolic alkalosis and
hypocalcemia.
Quality assessment
The quality of included studies was assessed by using
standard criteria: random sequence generation, alloca-
tion concealment, blinding of participants and personnel,
blinding of outcome assessment, incomplete outcome
data, selective reporting and other bias. When data
were missing or incomplete, the original authors were
contacted by written correspondence for clarification,
and any relevant information obtained was included
in the review.
Grading quality of evidence
Two investigators (CL and ZM) independently assessed
the quality of evidence for primary and secondary out-
comes according to the Grading of Recommendations
Assessment, Development and Evaluation (GRADE)
Working Group criteria [15]. Based on risk of bias,
indirectness, imprecision, inconsistency and publication
bias, the quality of the evidence was classified into four
categories (high, moderate, low and very low).
Statistical analysis
We calculated relative risks (RRs) with 95 % confidence
intervals (CIs) for dichotomous outcomes and mean dif-
ferences (MDs) with 95 % CIs for continuous outcomes.
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Heterogeneity across studies was quantified using the
I2 statistic, and the I2 > 50 % indicated significant het-
erogeneity [16]. The fixed-effect analytical model was
used to pool the results of trials with acceptable or
no heterogeneity. The random-effect model was used
to analyse the results of trials with significant hetero-
geneity, and the sensitivity analysis was performed to
test the robustness of results. Subgroup analysis was
conducted to investigate potential sources of between-
study heterogeneity. Publication bias was assessed
using the Begg and Egger tests. A P value less than
0.05 was considered to indicate a statistically signifi-
cant difference. All statistical analyses were performed
using Review Manager, version 5.1.2 (RevMan, The
Cochrane Collaboration, Oxford, UK). If the mean or
standard deviation of circuit survival time could not
be directly obtained from trials, we extracted the data
from published Kaplan-Meier survival curves [17] or
estimated the mean and deviation from the sample
size, median, range and/or interquartile range [18].
Trial sequential analysis
In a meta-analysis, random error increases the risk of
type I errors when sparse data are analysed and repeated
significance testing is conducted for the accumulated
data. To minimize this risk, monitoring boundaries were
applied to determine if the trial should be terminated
early under the condition of an amply small P value.
This is referred to as TSA [19, 20], a method that com-
bines an a priori information size calculation for a meta-
analysis with the adaptation of monitoring boundaries to
evaluate the accumulated evidence [21]. When the cu-
mulative Z-curve crosses the trial sequential monitoring
boundary or enters the futility area, a sufficient level of
evidence for the anticipated intervention effect may have
been reached, and no further trials are needed. If the
Z-curve does not cross any of the boundaries and the
required information size has not been reached, evi-
dence to reach a conclusion is insufficient, and more
trials are needed to confirm the results. We calcu-
lated information size as a diversity-adjusted required
information size, suggested by the diversity of the
intervention effect estimates among the included trials
[22]. For our TSA, we estimated the required infor-
mation size using α = 0.05 (two sided), β = 0.20 (power
80 %), the control event proportions calculated from
the heparin group and a relative risk reduction of
20 % in outcomes. If the random-effect model of
Sidik-Jonkman (SJ) and DerSimonian-Laird (DL) ap-
proaches produced different results, we conducted
meta-analyses with the two approaches and consid-
ered the implications of each of the two scenarios be-
ing true. The software TSA version 0.9 beta (http://
www.ctu.dk/tsa) was used for these analyses [23].
Results
Study enrolment and characteristics
Seven hundred and seventy potentially relevant studies
and 24 articles were retrieved for detailed assessment.
Ten articles were excluded because they were non-
randomized sequential trials. In total, 14 studies were
included in this meta-analysis (Fig. 1).
The characteristics and patient demographic data are
summarized in Table 1. All studies consistently included
patients with acute renal failure that required CRRT. Pa-
tients with severe liver failure, ischaemic hepatitis, high
risk of bleeding, severe coagulation disorders, history of
heparin allergy and HIT had been excluded from most
of the trials. Ten single-centre [11, 24–32] and four
multi-centre studies [12, 13, 33, 34] were identified.
These trials were reported between 2004 and 2015 and a
total of 1134 patients were included in this study.
Sample sizes of these trials varied considerably. Only
five trials [4, 11–13, 28, 33] included more than 100
patients. Seven trials [12, 24–27, 31, 34] reported the
total number of circuits. Baseline characteristics and
mean severity scores were similar between the two
groups. Nine trials [13, 24, 26–28, 30–33] applied
CVVH and four [11, 25, 29, 34] applied CVVHDF.
For the control group, ten trials [11, 13, 24, 25, 27, 29, 30,
32–34] used systemic heparin, three [12, 26, 31] regional
heparin and one [28] nadroparin. Various citrate protocols
and heparin anticoagulation doses were reported in these
trials.
Quality of studies
The details of the risk of bias tool are shown in Fig. 2.
Although all of these studies were RCTs, allocation con-
cealment was not performed. Owing to the nature of the
interventions, it was impossible for the medical staff to
perform the study blinded. GRADE Working Group
grades of evidence were low for primary outcomes and
secondary outcomes of adverse events. This was mainly
due to risk of bias and small sample sizes within studies.
Full GRADE profiles for the included evidence can be
found in Additional file 1.
Primary outcomes
Mortality
The main endpoint of mortality was defined in the
individual trials. If mortality was assessed at several
time points in a study, we used data from the latest
follow-up time for overall mortality assessment.
Seven trials [11–13, 25, 28, 33, 34] reported the mor-
tality of patients. Overall mortality in seven trials was
42.0 % (369/879). In the citrate group, 41.3 % (183/443) of
patients died compared with 42.7 % (186/436) in the
heparin group. There was no significant difference in mor-
tality between the citrate and heparin group (RR 0.97,
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95 % CI 0.84, 1.13, P = 0.72, Fig. 3a), and no significant
heterogeneity was found (Chi2 = 5.33, degrees of freedom
(df) = 6, P = 0.50; I2 = 0 %) (Fig. 3a). For the low hetero-
geneity, the fixed-effect model was used for TSA, and the
results showed that the cumulative Z-curve crossed the
futility boundary and entered the futility area (RR 0.97,
95 % CI 0.84, 1.13, P = 0.72) (Fig. 3b), establishing suffi-
cient and conclusive evidence and showing that further
trials were not required.
Circuit life span
Thirteen trials [11–13, 24–31, 33, 34] investigated the
circuit life span of the citrate versus heparin groups dur-
ing CRRT. The circuit life span was significantly longer
in the citrate group than in the heparin group, with a
mean difference of 15.69 h (95 % CI 9.30, 22.08, P < 0.01;
I2 = 96 %, P < 0.01) (Fig. 4a). Due to remarkable hetero-
geneity, two pre-set subgroup analyses were performed
for populations with CVVH or CVVHDF and pre-
dilution or post-dilution, respectively. Overall, in the
CVVH (mean difference (MD) 8.18, 95 % CI 3.86,
12.51, P < 0.01; I2 = 89 %, P < 0.01) (Fig. 4a) and pre-
dilution (MD 17.51, 95 % CI 9.85, 25.17, P < 0.01, I2 = 98 %,
P < 0.01) (Fig. 5a) subgroups, the circuit life span was
significantly longer in the citrate group than in the
heparin group. However, in the CVVHDF (MD 28.60,
95 % CI −3.52, 60.73, P = 0.08; I2 = 98 %, P < 0.01
Fig. 4a) and post-dilution (MD 13.06, 95 % CI −2.36,
28.48, P = 0.1; I2 = 94 %, P < 0.01 Fig. 5a) subgroups,
the circuit life span was similar in the two groups.
For the significant inter-trial heterogeneity, the
random-effect model of the DL and SJ methods were
used for TSA. When all trials were included, the DL
method results showed that the cumulative Z-curve
crossed both the conventional boundary for benefit
and the trial sequential monitoring boundary for
benefit and reached the required information size
(Fig. 5b). However, when using the SJ method, three
trials [26, 27, 30] were ignored in the interim looks
due to too low information use (<1.0 %)%). The re-
sults showed that the cumulative Z-curve crossed the
conventional boundary for benefit but not the trial
sequential monitoring boundary for benefit (Fig. 5c).
In the CVVH and pre-dilution subgroups, the DL
method results showed that the cumulative Z-curve
crossed both the conventional boundary for benefit
and the trial sequential monitoring boundary for
benefit (Fig. 4d and Fig. 5b). The SJ method results
showed the cumulative Z-curve crossed the conven-
tional boundary for benefit but not the trial sequen-
tial monitoring boundary for benefit (Fig. 4e and
Fig. 5c). In the CVVHDF and post-dilution sub-
groups, results from the two methods showed that
the cumulative Z-curve did not cross the conventional
boundary for benefit and did not enter the futility
boundary.
Fig. 1 Flow chart of the study selection. CNKI Chinese National Knowledge Infrastructure
Liu et al. Critical Care  (2016) 20:144 Page 4 of 13
Table 1 Characteristics of the included trials
Source Setting Exclusion Patients (M/F)/
circuits, number
Mean age, years Severity Modality; dilution;
blood flow (ml/min)
Filter material
Stucker et al. [11]
(2015; CH)




risk of bleeding and
sensitivity to heparin
C: 54 (32/22)/NR C: 60 ± 14a C: 28 ± 9 (APACHE II)/






H: 49 (32/17)/NR H: 65 ± 16a H: 29 ± 9 (APACHE II)/
65 ± 18 (SAPS)a
Gattas et al. [12]
(2015; AU)
Seven different ICUs Liver failure, pregnant
or breastfeeding, HIT,
chronic dialysis
C: 105 (74/31)/390 C: 66.4 ± 14.3a C: 25.6 ± 7.6 (APACHE II)a CVVHDF (61 %)
CVVH (29 %);
pre-dilution; 150 (52 %)
200 (23 %)
Aquarius or Prismaflex
H: 107 (72/35)/467 H: 66.8 ± 14.9a H: 25.0 ± 6.9 (APACHE II)a
Schilder et al. [13]
(2014; NL)
Ten different ICUs High bleeding risk,
other Therapeutic
anticoagulation, HIT
C: 66 (44/22)/NR C: 67 (36–87)b C: 23 (11–53) (APACHE II)/
10 (2–19) (SOFA)b
CVVH; pre-dilution; 180 NR
H: 73 (49/24)/NR H: 67 (23–85)b H: 25 (6–43) (APACHE II)/
11 (3–18) (SOFA)b









C: 64 ± 13a
H: 51 ± 17a
C: 80 (58–99) (APACHE III)b















C: 8 (NR)/26 C: 67 (52–77)b C: 40 (31–53) (SAPS)b CVVH; post-dilution; 175 1.6 m2 Highly
permeable PS
membraneH: 12 (/NR)/23 H: 64 (52–74)
b H: 42 (33–55) (SAPS)b
Lin XM et al. [29]
(2007; CN)
Adult mixed ICU NR C: 27 (16/11)/NR C: 63 ± 21a C: 82.5 ± 22.4 (APACHE III)a CVVHDF; pre-dilution;
100–180
PRISMA M-100 AN69
H: 23 (14/9)/NR H: 64 ± 19a H: 75.6 ± 18.3 (APACHE III)a
Cui W et al. [30]
(2011; CN)
Adult mixed ICU NR C: 23 (12/11)/NR C: 46.9 ± 6.1a C: NR CVVH; NR; NR PRISMA
H: 23 (13/10)/NR H: 47.2 ± 5.9a H: NR
Yang ST et al. [31]
(2014; CN)
Adult mixed ICU severe coagulopathy,
high risk of bleeding
C: 25 (NR)/81 61.7 ± 8.6 C: NR CVVH; pre-dilution;
200–250
Aquarius, HF1200
H: 21 (NR)/53 H: NR
Oudemans-van Straaten
et al. [28] (2009; NL)






C: 97 (66/31)/NR C: 73 (67–79)b C: 28 (27–30) (APACHE II)/
59 (55–62) (SAPS)b
CVVH; post-dilution; 220 1.9 m2 Cellulose
triacetate hollow
fibre membrane
N: 103 (70/33)/NR N: 73 (67–79)b N: 8 (27–29) (APACHE II)/
61 (58–64) (SAPS)b
Betjes et al. [24]
(2007; NL)




shock and liver failure
C: 1 (15/6)/70 C: 57.8 ± 4.2a C: 51.4 ± 4.1 (SAPS)a CVVH;post-dilution; 150 High-flux triacetate
H: 27 (19/8)/72 H: 55.2 ± 2.8a H: 51.0 ± 2.6 (SAPS)a






to citrate or heparin
C:10 (9/1)/10 71 (63.5–76.5)b SAPS: 41 (31–43)
APACHE II:17 (15–21)b
CVVH; pre-dilution; 150 APS650 PS hollow
fibre membrane
H:10 (9/1)/10








C: 16 (7/9)/36 C: 66.5 ± 14.5a C: 7.75 ± 3.53 (OD)a CVVHDF; pre-dilution; 125 Standard PRISMA
M-100 AN69









Table 1 Characteristics of the included trials (Continued)
Tiranathanagul et al. [32]
(2011; TH)







C: 10 (5/5)/NR C: 69.5(32–78)b C: 21 (18–29) (APACHE II)b CVVH; pre-dilution; 120 1.5 m2 Polyethersulfone
dialyzers
H: 10 (7/3)/NR H: 75.5 (18–87)b H: 22 (15–29) (APACHE II)b
Hetzel et al. [33]
(2011; DE)











9.95 ± 2.9 (SOFA)a
H: 83 (59/24)/NR H: 65 ± 12.5a H: 22.04 ± 5.5 (APACHE II)
9.95 ± 2.6 (SOFA)a
Abbreviations: M male, F female, APACHE Acute Physiology and Chronic Health Evaluation II, AU Australia, BE Belgium, C citrate, CA Canada, CH Switzerland, CN China, CRRT continuous renal replacement therapy, CVVH
continuous venovenous haemofiltration, CVVHDF continuous venovenous haemodiafiltration, DE Germany, H heparin, HF haemofiltration, HIT heparin-induced thrombocytopenia, N nadroparin, NL the Netherlands, NR











The adverse events included bleeding events, HIT,
metabolic alkalosis and hypocalcaemia (Table 2). For
acceptable heterogeneity, the fixed-effect analytical
model was used to pool the results. Compared with
systemic heparin, regional citrate was more efficacious
in decreasing the risk of bleeding, which was con-
firmed by TSA (the cumulative Z-curve crossed both
the conventional boundary for benefit and the trial
sequential monitoring boundary for benefit (see Add-
itional file 2)). However, there was no significant dif-
ference between the regional citrate and regional
heparin groups.
Although more HIT events were found in the hep-
arin group, the difference was not confirmed by TSA
(see Additional file 2).
The risk of metabolic alkalosis was similar between
these two groups, although TSA could not be per-
formed due to too few data. More episodes of hypo-
calcaemia were reported in the citrate group. Again,
TSA also could not be performed due to too few
data.
Cost-effectiveness
Two trials [13, 26] analysed the cost of each treat-
ment. Fealy et al. [26] reported that regional citrate
might yield a somewhat longer circuit life. However,
the magnitude of the gain in circuit life did not ap-
pear to be sufficient to offset the additional cost asso-
ciated with the use of citrate. Schilder et al. [13]
noted that the costs of the first 72 hours of pre-
scribed CVVH were lower in citrate-based CVVH,
which could be attributed to the lower cost of filter
sets and less labour due to the use of fewer filters
during treatment with citrate.
Inflammatory cytokines
Gattas et al. [12] reported that there was no signifi-
cant difference between the citrate and heparin
groups in the change of circulating levels of interleu-
kin (IL)-6, IL-8 and IL-10 between randomization and
the period 48–72 hours later. Tiranathanagul et al. [32]
compared the change in myeloperoxidase (MPO) and
cytokine production in patients with AKI undergoing
CVVH treatment. This RCT enrolled 20 patients who
were randomized into a regional citrate group (n = 10)
Fig. 2 Assessment for risk of bias. NL The Netherlands, AU Australia, CN China, DE Germany, CA Canada, BE Belgium, CH Switzerland, TH Thailand
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and a heparin group (n = 10). The results showed that
serum MPO and IL-8 levels were significantly decreased
in the citrate group. However, there was no survival bene-
fit identified.
Publication bias
We assessed the potential publication bias for the pri-
mary outcomes of mortality (P = 1.000 for the Begg
test, P = 0.209 for the Egger test) and circuit life span
(P = 0.150 for the Begg test, P = 0.361 for the Egger
test). No potential publication bias was observed
among the included trials (see Additional file 3).
Tests were not available for all subgroup datasets for
small sample sizes.
Discussion
This updated meta-analysis with the largest sample size
to date found: (1) there was no significant difference in
mortality between the two groups, which was confirmed
by TSA; (2) RCA significantly prolonged the circuit life
span in both the CVVH subgroup and pre-dilution
subgroup, although the TSA did not confirm this result;
(3) compared with systemic heparin, RCA significantly
decreased the bleeding risk, and the result was con-
firmed by TSA; (4) the incidence of metabolic alkalosis
was similar in these two groups; (5) although more
episodes of hypocalcaemia were observed in the citrate
group, no significant hypocalcaemia-related adverse
events were reported and (6) the cost was not signifi-
cantly increased in the citrate group.
Previous meta-analyses evaluating this topic have been
published. However, there are a number of differences
between the present study and the previously published
meta-analyses. First, this meta-analysis included an add-
itional eight trials performed since 2011. Furthermore,
Chinese trials were also included. One systematic review
[35] suggested that to include more evidence in meta-
analyses, clinical research published by scientists who
write in their native language rather than in English,
must be taken into account. Thus, the present meta-
analysis represents the latest and most comprehensive
study. Second, TSA was used to provide more conserva-
tive estimates and to better establish sufficient and con-
clusive evidence. Third, we evaluated the quality of
evidence for outcomes based on GRADE Working
Group criteria. The body of evidence will aid physicians
in making clinical decisions.
In this meta-analysis, mortality was not significantly
different between the two types of anticoagulants, and
the TSA results suggested that further trials were not re-
quired. Improving mortality is the ultimate goal of devel-
oping new adjuvant therapy. However, anticoagulation
Fig. 3 Effect of regional citrate versus heparin anticoagulation on mortality. a Mortality. b Fixed-effect model of trial sequential analysis for mortality. A
diversity-adjusted information size of 1021 participants calculated on the basis of a mortality rate of 42.66 % in the heparin group, relative risk reduction
20 %, α = 5 % (two sided), β = 20 %, I2 = 0 %. Complete blue line represents cumulative Z-curve, which crossed the futility boundary (complete red line)
and reached the futility area. AU Australia, DE Germany, CA Canada, NL The Netherlands, CH Switzerland, M-H Mantel-Haenszel
Liu et al. Critical Care  (2016) 20:144 Page 8 of 13
Fig. 4 Effect of regional citrate versus heparin anticoagulation on circuit life span (continuous venovenous haemofiltration (CVVH) and continuous
venovenous haemodiafiltration (CVVHDF) subgroup analysis). a Circuit life span. b-g Complete blue line represents the cumulative Z-curve, complete
red line represents the trial sequential monitoring boundary for benefit and etched green line represents the conventional boundary for benefit.
b The DerSimonian-Laird (DL) approach used for all trials. A diversity-adjusted information size of 1219 circuits was calculated on the basis of a
mean difference (MD) of 15.43, variance of 167.21, I2 = 98.11 %, α = 5 % (two sided) and β = 20 %. Cumulative Z-curve crosses the trial sequential
monitoring boundary for benefit and reaches the required information size. c The Sidik-Jonkman (SJ) approach used for all trials. A diversity-
adjusted information size of 5196 circuits was calculated on the basis of a MD of 17.14, variance of 167.21, I2 = 99.65 %, α = 5 % (two sided)
and β = 20 %. The cumulative Z-curve crosses the conventional boundary for benefit but not the trial sequential monitoring boundary for
benefit. d The DL approach used for the CVVH subgroup. A diversity-adjusted information size of 1033 circuits was calculated on the basis
of a MD of 8.18, variance of 110.0, I2 = 94.97 %, α = 5 % (two sided) and β = 20 %. The cumulative Z-curve crosses both the conventional
boundary and the trial sequential monitoring boundary. e The SJ approach used for the CVVH subgroup. A diversity-adjusted information
size of 3851 circuits was calculated on the basis of a MD of 11.08, variance of 110.0, I2 = 99.25 %, α = 5 % (two sided) and β = 20 %. The cumulative
Z-curve crosses the conventional boundary, but not the trial sequential monitoring boundary. f, g The DL and SJ approaches used for the
CVVHDF subgroup. The cumulative Z-curve does not cross the conventional boundary or the trial sequential monitoring boundary. NL The
Netherlands, CN, China, AU Australia, DE Germany, BE Belgium, IV Inverse Variance
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with regional citrate or heparin did not impact the sur-
vival rate. Thus, other methods that may decrease mor-
tality should be investigated.
This meta-analysis suggested that RCA may have an
advantage in prolonging the circuit life span, espe-
cially in the CVVH and pre-dilution subgroups. The
circuit life span is influenced by many factors, such
as the patient’s clinical condition, coagulation status,
the position and patency of the vascular access, the
choice of anticoagulant, modality of CRRT and filtra-
tion fraction [36]. These factors may also cause het-
erogeneity among trials. For the significant inter-trial
heterogeneity, the SJ and DL methods were used to
conduct TSA, with the former being more reliable.
TSA results suggested that additional well-designed
clinical trials are needed. Wu et al. [37] reported that
RCA plus low-dose dalteparin (40.4 ± 30.9 h) pro-
longed filter run time compared with RCA (21.2 ± 13.5 h,
Fig. 5 Effect of regional citrate versus heparin anticoagulation on circuit life span (pre-dilution and post-dilution subgroup analysis). a Circuit life
span. b-e Complete blue line represents the cumulative Z-curve, complete red line represents the trial sequential monitoring boundary for benefit
and etched green line represents the conventional boundary for benefit. b The DerSimonian-Laird (DL) approach used for the pre-dilution
subgroup (eight trials). A diversity-adjusted information size of 1355 circuits was calculated on the basis of a mean difference (MD) of
17.51, variance of 150.43, I2 = 98.82 %, α = 5 % (two sided) and β = 20 %. The cumulative Z-curve crosses the trial sequential monitoring
boundary for benefit and reaches the required information size. c The Sidik-Jonkman (SJ) approach used for the pre-dilution subgroup
(six trials: two trials ignored in the interim looks due to too low information use (<1.0 %)). A diversity-adjusted information size of 7106
circuits was calculated on the basis of a MD of 18.55, variance of 150.43, I2 = 99.8 %, α = 5 % (two sided) and β = 20 %. The cumulative
Z-curve crosses the conventional boundary but not the trial sequential monitoring boundary. d The DL approach used for the post-dilution subgroup
(three trials). A diversity-adjusted information size of 2232 circuits was calculated on the basis of a MD of 13.06, variance of 509.29, I2 = 95.79 %, α = 5 %
(two sided) and β = 20 %. The cumulative Z-curve does not cross the conventional boundary or trial sequential monitoring boundary. e The
SJ approach used for the post-dilution subgroup (two trials: one trial ignored in the interim looks due to too low information use (<1.0 %)).
A diversity-adjusted information size of 6516 circuits calculated on the basis of a MD of 15.76, variance of 509.29, I2 = 99.0 %, α = 5 % (two sided) and
β = 20 %. The cumulative Z-curve does not cross the conventional boundary or trial sequential monitoring boundary. AU Australia, DE Germany, CA,
Canada, CN, China, NL The Netherlands, IV Inverse Variance
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P = 0.006) only or normal-dose dalteparin (25.1 ± 24.0 h,
P = 0.040) only, without increasing the incidence of
anticoagulation-related complications. This may, there-
fore, represent a new anticoagulant approach to use in pa-
tients undergoing CRRT.
Four main adverse events were reported in this
study. Although this meta-analysis excluded patients
with liver failure, several studies have reported that
RCA can be safely used in patients with liver failure
and patients who are at a high risk of bleeding during
CRRT [38, 39]. One observational study [38], which
evaluated the safety and efficacy of RCA in ICU pa-
tients with liver failure, concluded that RCA-CVVHD
can be safely used in patients with liver failure. Fur-
thermore, the authors suggested that RCA can be
recommended as first-line anticoagulation for the ma-
jority of ICU patients. In addition, Shaikh et al. [39]
reported that CVVH with citrate-containing replace-
ment solution is safe and efficacious for critically ill
patients with AKI, who are at high risk of bleeding.
In terms of the mechanism of anticoagulation, citrate
acts as an anticoagulant in the extracorporeal system
through chelation of ionized calcium. When the ion-
ized calcium level is less than 0.35 mmol/L, the co-
agulation process will be interrupted. When ionized
calcium enters the systemic circulation; one molecule
of citrate will be metabolized into three molecules of
bicarbonate by the liver, muscle and kidney and will
affected the acid–base status, thus increasing the risk of
hypocalcaemia [40]. Although this meta-analysis showed
that more episodes of hypocalcaemia were found in the
citrate group, no significant hypocalcaemia-related adverse
events were reported. Furthermore, the ionized calcium
level was easily identified and controlled with monitoring.
The narrative result of cost-effectiveness in our meta-
analysis showed that CRRT with RCA had a time-saving
effect and helped to decrease the workload. The findings
of one observational study [41] are consisted with our
result. The authors performed a cost-effectiveness analysis
comparing citrate and heparin treatment and found lower
haemofilter-related costs and fewer anticoagulation-
associated complications, which minimized the total
CVVHDF cost (heparin, US$1,209 ± 517/day; citrate,
US$757 ± 268/day; P < 0.01). Cost-effectiveness is a critical
issue when choosing anticoagulants during CRRT for
critically ill patients with AKI. However, only two RCTs
evaluated cost-effectiveness differences between the two
groups. Future studies should therefore pay more atten-
tion to the issue of cost-effectiveness.
Our meta-analysis showed that the changes in IL-6,
IL-8 and IL-10 were not significantly different be-
tween the two groups [12]. Another study [42] re-
ported that the plasma level of neutrophil gelatinase-
associated lipocalin (NGAL) in critically ill patients
with AKI was not affected by CVVH or the anticoa-
gulation employed. Schilder et al. [43] confirmed that,
compared to the heparin group, less C5a and endo-
thelial MPO were released in the regional citrate group.
Inflammation and oxidative stress play important roles
in the initiation and extension phases of AKI [44].
Therefore, regional anticoagulation with citrate may
decrease the inflammatory response during CVVH in
critically ill patients with AKI, and may have some
benefit for patient survival.
Our analysis has some limitations. First, various mo-
dalities of CRRT and RCA protocols were used and
caused large clinical heterogeneity among these trials.
According to the clinical characteristics, we therefore
performed subgroup analyses to reduce and interpret
clinical heterogeneity. Second, double-blinding was not
performed because of the features of the trials, which
may result in performance and detection bias. Thus, we
used the GRADE approach to provide objective levels of
the body of evidence.
Conclusion
Between the regional citrate and heparin groups, no sig-
nificance difference was found in mortality, hypocalcae-
mia–related adverse events or inflammatory clearance.
However, regional citrate is more efficacious in prolong-
ing circuit life span and reducing the risk of bleeding.
Therefore, citrate should be recommended as the prior-
ity anticoagulant for critically ill patients who require
CRRT.
Table 2 Direct comparison of regional citrate with heparin on adverse events
Adverse events No. of studies No. of patients RR(95%CI) Heterogeneity Test for effect
(p value)Citrate Heparin I2 (p value)
Bleeding events 10 (11, 13, 24, 25, 27, 28, 29, 32, 33, 34)a 405 405 0.31(0.19, 0.51) 0% (0.56) <0.00001
3 (12, 26, 31)b 140 138 0.23 (0.03, 1.97) 0% (0.75) 0.18
HIT 5 (11, 12, 13, 28, 33) 409 415 0.41 (0.19, 0.87) 0% (0.73) 0.02
Metabolic alkalosis 7(11, 13, 24, 27, 28, 29, 34) 289 301 0.84 (0.47, 1.49) 40% (0.14) 0.55
Hypocalcemia 7 (11, 24, 27, 28, 29, 33, 34) 310 311 3.96 (1.50, 10.43) 0% (1.00) 0.005
CI confidence interval, HIT heparin induced thrombocytopenia, RR relative risk, a citrate versus systemic heparin; b citrate versus regional heparin
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Key messages
 Patient mortality was similar for regional citrate and
heparin anticoagulation during CRRT in the critically
ill patient with AKI, which was confirmed by TSA
 RCA significantly prolonged the circuit life span in
both the CVVH subgroup and pre-dilution subgroup,
although the TSA did not confirm this result
 Compared with systemic heparin, RCA significantly
decreased the bleeding risk, and the result was
confirmed by TSA
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